Clinical Trial Update: A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating abemaciclib plus tamoxifen or abemaciclib alone in women with metastatic breast cancer; results were posted in July 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (Verzenio) (abemaciclib)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-07-12